Overview
- HHS Secretary Robert F. Kennedy Jr. canceled the $766 million BARDA contract with Moderna, citing unresolved safety and testing questions over the mRNA-based H5N1 vaccine program.
- The Biden administration initially awarded Moderna $176 million in July 2024 and increased funding by $590 million in January 2025 to fast-track an mRNA bird flu shot.
- Public health specialists caution that ending mRNA support may hinder rapid production of adaptable vaccines as H5N1 continues to mutate and spread among dairy cattle, wildlife and farmworkers.
- Currently approved H5N1 vaccines rely on traditional egg- or cell-based manufacturing that can take months and may fail to match emerging virus strains.
- More than 70 U.S. cases have been reported in this outbreak and one death confirmed, recalling H5N1’s mortality rates of up to 54 percent in past human infections.